One month away! Join us for an R&D Day on July 14, 2026, at a.m. ET, where the Company will highlight its late-stage programs, including its ongoing trials in idiopathic pulmonary fibrosis, newly diagnosed chronic graft-versus-host disease, and newly diagnosed acute leukemia. Further, the Company will detail its new early-stage assets and broader plans to leverage its capabilities and resources to bring new treatment options to more patients. Catch all the details below: ir.syndax.com/news-releases/… A live replay will be available for a limited time.

#NewsAlert: Today, we highlighted key revumenib data presented at the #EHA2026 Congress. Collectively, the new data presented at EHA showcase the robust activity observed with revumenib, highlighting the potential to transform patient outcomes. Access the press release below: ir.syndax.com/news-releases/…

#NewsAlert: Today, we announced that data from the Phase 1/2 SAVE combination trial of an all-oral regimen in R/R NPM1m, KMT2Ar, or NUP98r AML were published in the Journal of Clinical Oncology and simultaneously presented at the European Hematology Association (EHA) 2026 Congress. Learn more by accessing the press release below: ir.syndax.com/news-releases/… #EHA2026 @JCO_ASCO @EHA_hematology

.@EHA_hematology’s #EHA2026 kicks off tomorrow and Syndax is joining! Visit us as Booth A4.06 to learn about our commitment to scientific excellence: ehaweb.org/connect-network/e…

Today marks #NationalCancerSurvivorsDay, an opportunity to come together to honor cancer survivors, celebrate life, and highlight the importance of ongoing care and advocacy beyond treatment. Meet Thomas Santos, a cancer survivor helping others find light in the darkest corners of their leukemia journey through honesty, vulnerability and resilience. #PassionforPatients #AcuteLeukemia

#HappeningSoon: On Monday, June 8, members of Syndax leadership will host a fireside chat during the Goldman Sachs 47th Annual Global Healthcare Conference. We invite you to attend the webcast at 2:00 p.m. ET to learn about our recent progress: ir.syndax.com/events/event-d… A live replay will be available for a limited time.

We’re thrilled to have participated in the 2026 @ASCO Annual Meeting (#ASCO26), where we enjoyed joining other industry leaders shaping the future of cancer care. Learn how Syndax is advancing innovative cancer therapies by visiting our website below: syndax.com/ #PassionforPatients #HemOnc

On #WorldBloodCancerDay, we shine a light on the importance of expanding access to novel therapies for patients in need. #DYK that most new therapies approved for adults are not tested in children, and for cancer drugs, the average delay between the first clinical trial in adults to the first clinical trial in children is 6.5 years? Together, we have partnered with @BloodCancerUtd to expand clinical trial access for historically excluded patient groups, including pediatrics. Learn about what’s possible when science, courage and pediatric patient advocacy come together by watching the below video. #PassionforPatients

The 2026 @ASCO Annual Meeting (#ASCO26) kicks off tomorrow and Syndax is joining! Visit us as Booth #26009 to learn how we’re reimagining cancer care: asco.org #HemOnc #Leukemia

#HappeningSoon: Tomorrow, members of Syndax leadership will host a fireside chat at the TD Cowen 7th Annual Oncology Innovation Summit. Join the webcast at 1:00 p.m. ET to learn what Syndax has in store for #ASCO26 and #EHA2026: ir.syndax.com/events/event-d… A live replay will be available for a limited time.

#NewsAlert: We’re thrilled to announce the acceptance of four revumenib abstracts for presentation at the American Society of Clinical Oncology (@ASCO) Annual Meeting. Our strong presence at ASCO highlights our scientific leadership and deep commitment to advancing care for patients. Learn more by accessing the press release below: ir.syndax.com/news-releases/… #ASCO26

During #NationalCancerResearchMonth, we underscore the importance and impact of cancer research in bringing hope to those who need it most. On the latest episode of the @AACR’s Believe in Progress podcast, Syndax’s Chief Scientific Officer and Founder Dr. Peter Ordentlich discusses what it takes to translate promising science into the future for patients. Tune in below! #PassionforPatients

Today marks #ClinicalTrialsDay, an opportunity to celebrate the enduring spirit of the clinical researchers who continue to adapt, innovate and press forward in service of patients and their families. Liz, Associate Director, Clinical Operations at Syndax, describes how this shared commitment to the people at the center of every study fuels scientific innovation. #ResearchRising #WeFlyHigherTogether

#NewsAlert: We’re thrilled to highlight the release of 12 abstracts showcasing new revumenib data on the @EHA_hematology website in advance of the #EHA2026 Congress. Collectively, these new data highlight our scientific leadership and bolster our confidence that we are positioned to transform the treatment paradigm for patients. Learn more by accessing the press release below: ir.syndax.com/news-releases/…

During #OncologyNursingMonth and on #NationalNursesDay, which marks the start of #NationalNursesWeek, we recognize the power of oncology nurses and the strength they inspire across every stage of cancer care. Hear from some of our Oncology Clinical Educators on what being a nurse at Syndax means to them. #WeFlyHigherTogether

During #NationalCancerResearchMonth, we celebrate the transformative impact of cancer research on millions of lives and highlight the critical role of scientists, clinicians and patients in driving innovation forward. Learn how Syndax is leading the way in reimagining cancer care through bold scientific innovation, collaboration, and our #PassionforPatients in this short video. #FirstinCompassion

#NewsAlert: Today, we reported our first quarter 2026 financial results and provided a business update. We delivered over $100 million in combined Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) net sales in the first quarter, highlighting strong demand for our medicines and advancing the company toward profitability. We are poised for continued commercial growth with robust prescriber bases, excellent payer coverage, and multiple evolving treatment patterns for both medicines. Learn more by reading our press release and joining our conference call today at 4:30 p.m. ET: ir.syndax.com/news-releases/… A live replay will be available after the call for a limited time.

#MarkYourCalendars: Join us for a conference call and webcast on Thursday, April 30 at 4:30 p.m. ET to hear the Syndax team discuss our first quarter 2026 financial results and provide a business update. Click the link below for more details: ir.syndax.com/news-releases/… A live replay will be available after the call.